Prostanoid production in endothelial and Kupffer liver cells from monocrotaline intoxicated rats

Human and Experimental Toxicology

Volumn 17, Issue 10, 1998, Pages 564-569

  Lemberg, Abraham ^a   Calabrese, Graciela ^a   Majowicz, Mónica ^a   Peredo, Horacio ^b   Scorticati, Camila ^a   Filinger, Esther ^a   Perazzo, Juan Carlos ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Instituto de Investigaciones Farmacologicas   (Argentina)

Author keywords

Endothelial cells; Kupffer cells; Liver injury; Monocrotaline; Prostanoids

Indexed keywords

MONOCROTALINE; PROSTAGLANDIN E2; PROSTAGLANDIN F; PROSTANOID; THROMBOXANE B2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; KUPFFER CELL; LIVER; LIVER INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CARCINOGENS; CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; KUPFFER CELLS; LIVER; MALE; MONOCROTALINE; PROSTAGLANDINS; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0031752820     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032798678907973     Document Type: Article

References (30)

1. Wilson DW et al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992; 22: 307-325.
2. Roth RA, Reindel JF. Lung vascular injury from monocrotaline pyrrol, a putative hepatic metabolite. Adv Exper Med Biol 1991; 283: 777-778.
3. Ito K, Nakashima T, Murakami K, Murakami T. Altered function of pulmonary endothelium following monocrotaline-induced lung vascular injury in rats. Br J Pharmacol 1988; 94: 1175-1183.
4. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline: pulmonary hypertension. Am J Physiol 1988; 255: H 1484-H 1491.
5. Ghodsi F, Will JA.Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Phvsiol 1981; 240: H149-H155.
6. Kim HY et al. Structural influences on pyrrolizidine alkaloid-induced cytopathology. Toxicol Appl Pharmacol 1993; 122: 61-69.
7. Stillman AE, Huxtable R, Consroe P et al. Hepatic veno-occlusive disease due to Pyrrolizine (Senecio) poisoning in Arizona. Gastroenterology 1977; 73: 329-352.
8. Epstein RB, Min KW, Anderson SL, Syzek L. A canine model for hepatic veno-occlusive disease. Transplantation 1992; 54: 12-16.
9. Jones EA, Summerfield JA. The Liver: Biology and Pathology. Second Ed. Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA (eds.) Chapter 37: Kupffer cells, 683-704, Raven Press, Ltd., New York, 1988.
10. Brouwer A, Wisse EE, Knook DL. The Liver: Biology and Phatology. Second Ed. Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA (eds.) Chapter 36: Sinusoidal endothelial cells and perisinusoidal Fat-storing cells, 665-682, Raven Press, Ltd. New York, 1988.
11. Eyhorn S et al. Kupffer cells and other liver sinusoidal cells; 83-84. Wise E, Knook DL (eds.) Elseiver/ North Holland, Amterdam. 1997.
12. Kim A, Knook DL, Wise E, (eds.). Cells of Hepatic Sinusoid, Vol I. Kupffer Cell Foundation, Rijswijk, The Netherlands. 1986.
13. Decker K, Eicosanoids, signal molecules of liver cells. Semin Liver Dis 1985; 5: 175-190.
14. Kuiper J, Zijlstra F, Kamps J, Van Berkel T. Identification of Prostaglandin D2 as the major eicosanoid from liver endothelial and Kupffer cells. Biochim Biophys Acta 1988; 959: 143-152.
15. Groszmann RJ, Vorobioff J, Riley E. Splanchnic haemodynamics in Portal Hypertensive rats: measurements with gamma labeled microspheres. Am J Physiol 1982; 242 G: 156-160.
16. Henriksen JC, Ring-Larsen H, Christensen NJ. circulating noradrenaline and central haemodynamics in patients with cirrhosis. Scand J Gastroenterol 1985; 20: 1185-1190.
17. Pertoft H, Smedsrod B. Cell separation: Methods and. Chapter I: Separation and characterization of liver cells. Academic Press, Inc 1987.
18. Knook D, Blansjaar N, Sleyster E. Isolation and characterization of Kupffer and endothelial cells from the rat liver. Exp Cell Res 1977; 109, 317-329.
19. Widman J, Cotran R, Fahimi D. Mononuclear phagocytes (Kupffer cells) and endotholial cells. J Cell Biol 1972; 52, 159-170.
20. Peredo AH, Enero MA. Effect of endothelinium removal of basal and muscarinic cholinergic stimulated rat. Mesenteric: Vascular bed prostanoid synthesis. Prostaglandins, Leuk. and essential Fatty Acids 1993; 48: 373-378.
21. Hilliken KS, Bell TG, Roth RA. Monocrotaline Pyrrol-induced pulmonary hypertension in Fownloaded rats with platelet storage pool deficiency: 5-hydroxy tryptamine uptake by isolated perfused lung. Thrombosis and Haemostasis 1983; 50: 844-847.
22. Ono S, Voolkel NF. PAF antagonists inhibit monocrotaline induced lung injury and Pulmonary Hypertension. J Appl Physiol 1991; 71: 2483-2492.
23. Plestina R, Stoner HB. Pulmonary edema in rats given monocrotaline pyrrol. J Pathol 1972; 106: 235-240.
24. DeLeve L, Wang X, Kuhlenkamp J, Kaplowitz N. Selective toxicity to sinusoidal endothelial cells by agents that cause hepatic veno-occlusive disease is modulated by GSH: azathioprine and monocrotaline. Hepatology 1996; 23: 589-599.
25. Glowaz SL, Michnika M, Huxtable RJ. Detection of a reactive pyrrole in the hepatic metabolism of the pyrrolizidine alkaloid, monocrotaline. Toxicol Appl Pharmacol 1992; 115: 168-173.
26. Ghanem C. Ghisolfi C, Marabotto L. et al. Lipid changes in hepatic microsomes and its relationship to P-Nitrophenol in an experimental model of portal hypertension, Arch Physiol Biochem 1997; 105, 6: 1-4.
27. Guarner C, Soriano G. Prostaglandin and Portal Hypertension. Prostaglandins, Leuk and essential Fatty Acids 1993; 48: 203-206.
28. Sitzmann JV, Li S, Adkinson F. Evidence for role of Prostacyclin as a systemic hormone in Portal Hypertension. Surgery 1991; 109: 149-153.
29. Wu Y, Cartland Burns R, Sitzmann JV. Effects of Nitric Oxide and ciclooxigenase inhibition on splanchnic haemodynamics in Portal Hypertension. Hepatology 1993; 18: 1416-1421.
30. Oberti R, Segni P, Caimail S. et al. Role of Prostacyclin in haemodynamic alterations in conscious rats with extrahepatic or intrahepatic Portal Hypertension. Hepatology 1993; 18: 621-627.